Stay updated with breaking news from Nsclc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Patients with distant recurrent non–small cell lung cancer (NSCLC) had significantly better overall survival (OS) than patients who had de novo disease.
Specialists engage in a conversation regarding the treatment duration and the effectiveness of the current two-year approach.
The single-arm approval study reported an objective response rate of 75% among treatment-naive patients.
The march of immunotherapy into a wider range of malignancies, as well as the smarter use of chemotherapy and novel targeted drugs, will be among the key highlights at the ESMO Congress 2023.
Just as Wall Street had begun mulling the possible fallout of the regulatory vote against full U.S. FDA clearance for Amgen Inc.’s KRAS G12C therapy for non-small-cell lung cancer, a new – albeit not entirely unexpected – development cropped up in the space. Mirati Therapeutics Inc. disclosed Oct. 9 that Bristol Myers Squibb Co. (BMS) is offering to take over the firm in a deal that could be worth as much as $5.8 billion, historically one of the larger takeovers for 2023.